Maintenance therapy for ovarian cancer also effective in other patient groups

23 December 2019

On 19 December, the New England Journal of Medicine, a leading medical publication, published two studies which Prof. Dr. Ignace Vergote, head of gynaecology and obstetrics at UZ Leuven, participated in. This relates to two phase 3 clinical studies investigating the impact of an existing maintenance therapy on the survival rate of various groups of patients with advanced ovarian cancer.

Afbeelding van de baarmoeder en eierstokken

Studies have shown that maintenance therapy with PARP inhibitors is also effective in patients without a BRCA gene mutation.

UZ Leuven treats approximately 120 patients with newly diagnosed ovarian cancer each year. About 30% of these patients have a BRCA1 or BRCA2 gene mutation in the tumour. Following initial treatment involving an operation and chemotherapy, the as yet not reimbursed maintenance therapy for these patients is based on so-called ‘PARP inhibitors’. They block the natural DNA repair mechanisms in cancer cells, resulting in an accumulation of faults in the DNA so that the tumour stops growing and eventually dies off.

Until recently only patients with a BRCA1 or BRCA2 mutation showed notable results.

The two recent phase 3 studies, referred to as ENGOT-ov26/PRIMA and ENGOT-ov25/PAOLA-1, demonstrated that PARP inhibitors also have a positive impact on the survival rate of patients without BRCA mutations. The PRIMA study corroborated that the PARP inhibitor Niraparib extends disease free survival not only in patients with BRCA mutations, but also in another group of patients with suppressed DNA repair (homologous recombination deficiency). This means that more than half of all patients with ovarian cancer would be suitable for treatment with a PARP inhibitor. The PAOLA-1-study showed that the survival rate in the same patient groups also dramatically increases if the PARP inhibitor Olaparib is combined with a drug that inhibits the formation of blood vessels (Bevacizumab).

Reimbursement to be extended

The side effects of PARP inhibitors were relatively mild and acceptable for all patients, which meant that the therapy was well tolerated. The necessary steps can now be undertaken to extend reimbursement of costs to patients with a new diagnosis of ovarian cancer and a BRCA gene mutation or homologous recombination deficiency.

Read the published PRIMA and PAOLA trials.

More about "Gynaecology and obstetrics"

Cancer during pregnancy has no serious impact on the child’s brain development

21 October 2020
UZ Leuven has set up a large-scale follow-up trial examining the influence of cancer during pregnancy on the brain development of children. Cancer and chemotherapy during a pregnancy hardly appeared to influence the child’s brain.
More info
More about "Gynaecology and obstetrics"

Visit the delivery room and maternity unit

2 September 2019
Participate in a virtual tour and discover where your baby will make its entry into the world. A restful and comfortable environment where you will receive the best possible care. Not only will you find out what it looks like, you will also be given useful information on the way we operate.
More info
More about "Gynaecology and obstetrics"

Less sedentary lifestyle during pregnancy results in lower fat percentage in the babies of obese mothers

14 March 2019
The European DALI trial has shown that when obese women adopt a less sedentary lifestyle during pregnancy, their babies have a lower fat percentage at birth. This demonstrates for the first time that there is a connection between lifestyle during the pregnancy and the baby's fat percentage.
More info
Last edit: 24 January 2020